Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04150939 · ClinicalTrials.gov registry record · NA

Cryoablation for the Treatment of Metastatic Cancer

A NA study of Metastatic Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT04150939 is a NA study of Metastatic Malignant Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants, below the 337-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04150939, a NA study of Metastatic Malignant Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This interventional trial studies the effectiveness of adding cryoablation treatment in patients who are receiving standard of care immunotherapy to treat cancer that is has spread to other parts of the body (metastatic). Cryoablation uses a probe that freezes the tissue around the tumor to try to kill the cancer cells. Using cryoablation to treat cancerous lesions may help to kill the cancer cells.

Interventions

  • PROCEDURE Core Biopsy
  • PROCEDURE Cryosurgery
  • DRUG Immunotherapeutic Agent

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-12-23
Est. Completion 2026-08-31
Phase NA

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT04150939

The ClinicalTrials.gov registry entry for NCT04150939 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 337-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (96% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Malignant Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Core Biopsy is the first listed.

NCT04150939 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04150939 about?

NCT04150939 is a clinical study titled "Cryoablation for the Treatment of Metastatic Cancer". This interventional trial studies the effectiveness of adding cryoablation treatment in patients who are receiving standard of care immunotherapy to treat cancer that is has spread to other parts of the body (metastatic). Cryoablation uses a probe that freezes the tissue around the tumor to try to k...

What is the current status of trial NCT04150939?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2019-12-23. Estimated completion is 2026-08-31.

What conditions does trial NCT04150939 study?

This clinical trial studies the following conditions: Metastatic Malignant Neoplasm.

What interventions are being tested in trial NCT04150939?

The interventions under investigation include: Core Biopsy (PROCEDURE), Cryosurgery (PROCEDURE), Immunotherapeutic Agent (DRUG).

Who is sponsoring clinical trial NCT04150939?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04150939 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Malignant Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.